ArticleJournal of virology2015
Characterization of a proteolytically stable D-peptide that suppresses herpes simplex virus 1 infection: implications for the development of entry-based antiviral therapy.
Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Blocking HSV-1 glycoprotein K binding to signal peptide peptidase reduces virus infectivity in vitro and in vivo.PLoS pathogens · 2021Article
- Heparanase as a potential player in SARS-CoV-2 infection and induced coagulopathy.Bioscience reports · 2021Review
- Review
- A Multifunctional Peptide FromFrontiers in molecular biosciences · 2021Article
- "What Doesn't Kill You Makes You Stronger": Future Applications of Amyloid Aggregates in Biomedicine.Molecules (Basel, Switzerland) · 2020Review
- Importance of structure-based studies for the design of a novel HIV-1 inhibitor peptide.Scientific reports · 2020Article
- Vaccines and Therapies in Development for SARS-CoV-2 Infections.Journal of clinical medicine · 2020Review
- Prior inhibition of AKT phosphorylation by BX795 can define a safer strategy to prevent herpes simplex virus-1 infection of the eye.The ocular surface · 2020Article
- Herpes Simplex Virus: The Hostile Guest That Takes Over Your Home.Frontiers in microbiology · 2020Review
- Enhanced inhibition of influenza virus infection by peptide-noble-metal nanoparticle conjugates.Beilstein journal of nanotechnology · 2019Article
- An off-target effect of BX795 blocks herpes simplex virus type 1 infection of the eye.Science translational medicine · 2018Article
- Cultured corneas show dendritic spread and restrict herpes simplex virus infection that is not observed with cultured corneal cells.Scientific reports · 2017Article
- Genital Herpes: Insights into Sexually Transmitted Infectious Disease.Microbial cell (Graz, Austria) · 2016Review
- Extended Release of an Anti-Heparan Sulfate Peptide From a Contact Lens Suppresses Corneal Herpes Simplex Virus-1 Infection.Investigative ophthalmology & visual science · 2016Article
- Review
- Cell entry mechanisms of HSV: what we have learned in recent years.Future virology · 2015Article
- Basal Autophagy Is Required for Herpes simplex Virus-2 Infection.Scientific reports · 2015Article
- Autophagy stimulation abrogates herpes simplex virus-1 infection.Scientific reports · 2015Article
- Article
- Herpes Simplex Virus-1 Fine-Tunes Host's Autophagic Response to Infection: A Comprehensive Analysis in Productive Infection Models.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Uncontrolled herpes simplex virus 1 (HSV-1) infection can advance to serious conditions, including corneal blindness or fatal encephalitis. Here, we describe a highly potent anti-HSV-1 peptide (DG2) that inhibits HSV-1 entry into host cells and blocks all aspects of infection. Importantly, DG2 is highly resistant to proteases and shows minimal toxicity, paving the way for prophylactic or therapeutic application of the peptide in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.